Rare targetable drivers (RTDs) in non-small cell lung cancer (NSCLC): Outcomes with immune check-point inhibitors (ICPi)-Reference-Cited by-同舟云学术

Rare targetable drivers (RTDs) in non-small cell lung cancer (NSCLC): Outcomes with immune check-point inhibitors (ICPi)

Published:2018-10 Issue: Volume:124 Page:117-124
ISSN:0169-5002
Container-title:Lung Cancer
language:en
Short-container-title:Lung Cancer

Author:

Dudnik Elizabeth,Bshara Elias,Grubstein Ahuva,Fridel Ludmila,Shochat Tzippy,Roisman Laila C.^ORCID,Ilouze Maya,Rozenblum Anna Belilovski,Geva Smadar,Zer Alona,Rotem Ofer,Allen Aaron M.^ORCID,Peled Nir

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference30 articles.

1. Nivolumab versus docetaxel in advanced nonsquamous non–small-cell lung cancer;Borghaei;N. Engl. J. Med.,2015

2. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non small-cell lung cancer (KEYNOTE-010): a randomised controlled trial;Herbst;Lancet,2016

3. OAK Study Group. Atezolizumab versus docetaxel in patients with previously treated non-small cell lung cancer (OAK): a phase 3, open-label, multicentre randomized controlled trial;Rittmeyer;Lancet,2017

4. KEYNOTE-024 Investigators. Pembrolizumab versus chemotherapy for PD-L1–positive non–small cell lung cancer;Reck;N. Engl. J. Med.,2016

5. KEYNOTE-189 investigators. Pembrolizumab plus chemotherapy in metastatic non–small-cell lung cancer;Gandhi;N. Engl. J. Med.,2018

Cited by 51 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Non-Small-Cell Lung Cancers (NSCLCs) Harboring RET Gene Fusion, from Their Discovery to the Advent of New Selective Potent RET Inhibitors: “Shadows and Fogs”;Cancers;2024-08-19

2. Efficacy and tolerability of capmatinib in a very elderly patient with metastatic NSCLC harboring a MET exon 14 mutation;Personalized Medicine;2024-07-03

3. Efficacy of immunotherapy in RET fusion-positive NSCLC: A meta-analysis;Heliyon;2024-07

4. Prognostic and predictive biomarkers with therapeutic targets in nonsmall-cell lung cancer: A 2023 update on current development, evidence, and recommendation;Journal of Oncology Pharmacy Practice;2024-04-05

5. Early-Stage Non-Small Cell Lung Cancer: Prevalence of Actionable Alterations in a Monocentric Consecutive Cohort;Cancers;2024-04-03